000 | 01999 a2200529 4500 | ||
---|---|---|---|
005 | 20250516102219.0 | ||
264 | 0 | _c20120918 | |
008 | 201209s 0 0 eng d | ||
022 | _a1560-7917 | ||
024 | 7 |
_a10.2807/ese.17.27.20210-en _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aWang, B | |
245 | 0 | 0 |
_aFrequency of oseltamivir resistance in Sydney, during the Newcastle outbreak of community transmitted oseltamivir-resistant influenza A(H1N1)pdm09 virus, Australia, June to August 2011. _h[electronic resource] |
260 |
_bEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin _cJul 2012 |
||
500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAdult |
650 | 0 | 4 |
_aAntiviral Agents _xtherapeutic use |
650 | 0 | 4 |
_aAustralia _xepidemiology |
650 | 0 | 4 | _aBase Sequence |
650 | 0 | 4 |
_aCommunity-Acquired Infections _xepidemiology |
650 | 0 | 4 |
_aDNA Viruses _xdrug effects |
650 | 0 | 4 | _aDisease Outbreaks |
650 | 0 | 4 | _aDrug Resistance, Viral |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aInfluenza A Virus, H1N1 Subtype _xdrug effects |
650 | 0 | 4 |
_aInfluenza, Human _xdrug therapy |
650 | 0 | 4 | _aMale |
650 | 0 | 4 |
_aMutation _xdrug effects |
650 | 0 | 4 |
_aNeuraminidase _xgenetics |
650 | 0 | 4 |
_aOseltamivir _xtherapeutic use |
650 | 0 | 4 | _aPolymerase Chain Reaction |
650 | 0 | 4 | _aPrevalence |
650 | 0 | 4 |
_aRNA, Viral _xanalysis |
650 | 0 | 4 | _aSequence Analysis, DNA |
700 | 1 | _aTaylor, J | |
700 | 1 | _aRatnamohan, M | |
700 | 1 | _aMcPhie, K | |
700 | 1 | _aKesson, A | |
700 | 1 | _aDixit, R | |
700 | 1 | _aBooy, R | |
700 | 1 | _aHurt, Ac | |
700 | 1 | _aSaksena, Nk | |
700 | 1 | _aDwyer, D E | |
773 | 0 |
_tEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin _gvol. 17 _gno. 27 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.2807/ese.17.27.20210-en _zAvailable from publisher's website |
999 |
_c21940525 _d21940525 |